The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions

Human Pathology

Volumn 46, Issue 1, 2015, Pages 1-8

  Davidson, Ben ^a,b   Holth, Arild ^a   Hellesylt, Ellen ^a   Tan, Tuan Zea ^c   Huang, Ruby Yun Ju ^c,d   Tropé, Claes ^a,b   Nesland, Jahn M ^a,b   Thiery, Jean Paul ^c,e,f  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

Chemoresistance; Effusion; Epithelial mesenchymal transition; Ovarian carcinoma; Survival

Indexed keywords

CD56 ANTIGEN; NERVE CELL ADHESION MOLECULE; P CADHERIN; PLATINUM COMPLEX; UVOMORULIN; VIMENTIN; ANTINEOPLASTIC AGENT; HOMEODOMAIN PROTEIN; PADGEM PROTEIN; SELP PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER; ZEB1 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA CELL; DRUG RESISTANCE; EFFUSION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARIAN SEROUS CARCINOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM METASTASIS; PLEURA EFFUSION; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; STEM CELL; TREATMENT RESPONSE; VERY ELDERLY; AGE; BIOPSY; CANCER GRADING; CANCER STEM CELL; CHEMISTRY; CHI SQUARE DISTRIBUTION; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOPSY; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; NEOPLASTIC STEM CELLS; NEURAL CELL ADHESION MOLECULES; OVARIAN NEOPLASMS; P-SELECTIN; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 84916229944     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2014.10.004     Document Type: Article

References (36)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. B.T. Hennessy, R.L. Coleman, and M. Markman Ovarian cancer Lancet 374 2009 1371 1382
3. B. Davidson Ovarian/primary peritoneal carcinoma Davidson B Firat P Michael CW Serous effusions - etiology, diagnosis, prognosis and therapy 2012 Springer London 47 68
4. A. Latifi, R.B. Luwor, and M. Bilandzic Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors PLoS One 7 2012 e46858
5. V. Vathipadiekal, D. Saxena, S.C. Mok, P.V. Hauschka, L. Ozbun, and M.J. Birrer Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer PLoS One 7 2012 e29079
6. H. Acloque, M.S. Adams, K. Fishwick, M. Bronner-Fraser, and M.A. Nieto Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease J Clin Invest 119 2009 1438 1449
7. J.P. Thiery Epithelial-mesenchymal transitions in tumour progression Nat Rev Cancer 2 2002 442 454
8. J.P. Thiery, H. Acloque, R.Y. Huang, and M.A. Nieto Epithelial-mesenchymal transitions in development and disease Cell 139 2009 871 890
9. R. Kalluri, and R.A. Weinberg The basics of epithelial-mesenchymal transition J Clin Invest 119 2009 1420 1428
10. M. Zeisberg, and E.G. Neilson Biomarkers for epithelial-mesenchymal transitions J Clin Invest 119 2009 1429 1437
11. B. Davidson, A. Berner, and J.M. Nesland E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions J Pathol 192 2000 460 469
12. S. Elloul, I. Silins, C.G. Tropé, A. Benshushan, B. Davidson, and R. Reich Expression of E-cadherin transcriptional regulators in ovarian carcinoma Virchows Arch 449 2006 520 528
13. B. Davidson, C.G. Tropé, and R. Reich Epithelial-mesenchymal transition in ovarian carcinoma Front Oncol 2 2012 33
14. T.Z. Tan, Q.H. Miow, and R.Y. Huang Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer EMBO Mol Med 5 2013 983 998
15. V.G. Tusher, R. Tibshirani, and G. Chu Significance analysis of microarrays applied to the ionizing radiation response Proc Natl Acad Sci U S A 98 2001 5116 5121
16. WHO Classification of Tumours of Female Reproductive Organs R.J. Kurman, M.L. Carcangiu, and C.S. Herrington 2014 IARC Lyon, France 17 24
17. T.E. Hetland, A. Holth, J. Kærn, V.A. Flørenes, C.G. Tropé, and B. Davidson HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors and solid metastases Virchows Arch 460 2012 505 513
18. K. Brusegard, H.T. Stavnes, D.A. Nymoen, K. Flatmark, C.G. Tropé, and B. Davidson Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma Virchows Arch 460 2012 193 202
19. A. Gheldof, and G. Berx Cadherins and epithelial-to-mesenchymal transition Prog Mol Biol Transl Sci 116 2013 317 336
20. R.Y. Huang, M.K. Wong, and T.Z. Tan An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530) Cell Death Differ 4 2013 e915
21. L.A. Carey, E.C. Dees, and L. Sawyer The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2007 2329 2334
22. D.P. Silver, A.L. Richardson, and A.C. Eklund Efficacy of neoadjuvant cisplatin in triple-negative breast cancer J Clin Oncol 28 2010 1145 1153
23. Q.H. Miow, T.Z. Tan, and J. Ye Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer Oncogene 2014 10.1038/onc.2014.136
24. H. Kajiyama, K. Shibata, and M. Terauchi Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells Int J Oncol 31 2007 277 283
25. A.M. Haslehurst, M. Koti, and M. Dharsee EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer BMC Cancer 12 2012 91
26. L. Rosanò, R. Cianfrocca, and F. Spinella Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells Clin Cancer Res 17 2011 2350 2360
27. W.G. McCluggage, M. McKenna, and H.A. McBride CD56 is a sensitive and diagnostically useful immunohistochemical marker of ovarian sex cord-stromal tumors Int J Gynecol Pathol 26 2007 322 327
28. E.Y. Cho, Y. Choi, S.W. Chae, J.H. Sohn, and G.H. Ahn Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms Pathol Int 56 2006 62 70
29. S. Zecchini, L. Bombardelli, and A. Decio The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling EMBO Mol Med 3 2011 480 494
30. D.J. Brennan, S. Ek, and E. Doyle The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer Eur J Cancer 45 2009 1510 1517
31. S. Sernbo, E. Gustavsson, and D.J. Brennan The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation BMC Cancer 11 2011 405
32. S. Runz, S. Keller, and C. Rupp Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM Gynecol Oncol 107 2007 563 571
33. M.Q. Gao, Y.P. Choi, S. Kang, J.H. Youn, and N.H. Cho CD24(+) cells from hierarchically organized ovarian cancer are enriched in cancer stem cells Oncogene 29 2010 2672 2680
34. + ovary cancer cells exhibit an invasive mesenchymal phenotype Biochem Biophys Res Commun 432 2013 333 338
35. G. Kristiansen, C. Denkert, K. Schlüns, E. Dahl, C. Pilarsky, and S. Hauptmann CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival Am J Pathol 161 2002 1215 1221
36. E. Meng, B. Long, and P. Sullivan CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival Clin Exp Metastasis 29 2012 939 948